Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Core Viewpoint - Nuvectis Pharma, Inc. has initiated an underwritten public offering of its common stock to support the development of its clinical-stage drug candidates and other corporate purposes [1][2]. Group 1: Offering Details - The public offering will consist of shares solely offered by Nuvectis, with an option for underwriters to purchase an additional 15% of the shares within 30 days [1]. - Lucid Capital Markets is serving as the sole book runner for the offering [2]. - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. Group 2: Use of Proceeds - Nuvectis plans to utilize the net proceeds from the offering for advancing the development of drug candidates NXP800 and NXP900, hiring personnel, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions with unmet medical needs [5]. - The company is advancing two clinical-stage drug candidates: NXP800, which is in a Phase 1b trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, and NXP900, currently in a Phase 1a dose escalation study [5].